Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients
- 1 March 2005
- journal article
- Published by Elsevier in Kidney International
- Vol. 67 (3) , 1171-1178
- https://doi.org/10.1111/j.1523-1755.2005.00184.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 2004
- FGF-23 in patients with end-stage renal disease on hemodialysisKidney International, 2004
- FGF-23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate HomeostasisJournal of Bone and Mineral Research, 2004
- Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteersKidney International, 2003
- Regulation of Fibroblastic Growth Factor 23 Expression but Not Degradation by PHEXJournal of Biological Chemistry, 2003
- Fibroblast Growth Factor 23 in Oncogenic Osteomalacia and X-Linked HypophosphatemiaNew England Journal of Medicine, 2003
- Reduced p21, p27 and vitamin D receptor in the nodular hyperplasia in patients with advanced secondary hyperparathyroidism1Kidney International, 2002
- Clonal Chromosomal Defects in the Molecular Pathogenesis of Refractory Hyperparathyroidism of UremiaJournal of the American Society of Nephrology, 2002
- Identification of a Novel Fibroblast Growth Factor, FGF-23, Preferentially Expressed in the Ventrolateral Thalamic Nucleus of the BrainBiochemical and Biophysical Research Communications, 2000
- Serial Evaluation of Parathyroid Size by Ultrasonography Is Another Useful Marker for the Long-Term Prognosis of Calcitriol Pulse Therapy in Chronic Dialysis PatientsNephron, 1994